Intratio
Quantitative Research
Skip to main content
AI Market Summary
Loading market intelligence...
  • Sign in
    My account
    Logout
AI 90-DAY FORECAST
NEUTRAL SIGNAL
██.█% Sign up free to reveal

Crispr Therapeutics Ag (CRSP) AI Forecast

Our AI analyzed Crispr Therapeutics Ag. Create a free account and follow it to see the 90-day price prediction.

✓ Free account • ✓ 30-day free trial

$CRSP Neutral Signal Full forecast available
Sign Up Free

Crispr Therapeutics Ag (CRSP) Stock Forecast 2025

Crispr Therapeutics Ag (CRSP) AI Stock Price Forecast & Investment Analysis

Crispr Therapeutics Ag Stock Price Chart and Technical Analysis

Loading chart...

Crispr Therapeutics Ag (CRSP) - Comprehensive Stock Analysis & Investment Research

Deep dive into Crispr Therapeutics Ag's business profile, financial performance, AI predictions, and competitive positioning to make informed investment decisions.

Analysis updated on July 27, 2026, 3:40 p.m. (UTC)

Crispr Therapeutics Ag Investment Summary

When evaluating whether Crispr Therapeutics Ag (CRSP) represents a compelling investment opportunity, investors must consider multiple factors including the company's financial health, market position, growth prospects, and what our AI-powered predictive models suggest about its near-term price trajectory.

Company Profile

Crispr Therapeutics Ag (CRSP) operates within the Life Sciences sector, specifically in the Biological Products, (No Diagnostic Substances) industry. . With a market capitalization of $5 billion, the company is a mid-cap stock that typically offers a balance between growth potential and established business operations.

Financial Performance Analysis

Our comprehensive financial analysis covers Crispr Therapeutics Ag's revenue, profitability metrics, balance sheet strength, and cash flow generation...

AI Price Predictions

Get AI-powered 7-day, 30-day and 90-day price forecasts for Crispr Therapeutics Ag along with confidence scores and detailed analysis...

Investment Considerations

Expert analysis of whether Crispr Therapeutics Ag is suitable for your investment objectives, risk tolerance, and time horizon...

Continue Reading Full Analysis

Get the complete investment breakdown for Crispr Therapeutics Ag

Sign Up Free
Corporate Identity

Crispr Therapeutics Ag (Stock Symbol: CRSP) is a prominent company operating within the Life Sciences sector, with a specific focus on the Biological Products, (No Diagnostic Substances) industry. The company's shares are publicly traded on the Nasdaq exchange.

Leadership & Workforce

Detailed information about Crispr Therapeutics Ag's leadership team, workforce size, and organizational structure...

Market Classification

Market capitalization analysis and stock classification (mega-cap, large-cap, mid-cap, small-cap) for Crispr Therapeutics Ag...

Sector & Industry Analysis

In-depth sector dynamics and industry context for Crispr Therapeutics Ag...

Unlock Full Company Profile

Get complete details about Crispr Therapeutics Ag

Sign Up Free
Revenue & Growth Analysis

Crispr Therapeutics Ag generates annual revenues of $4 million , representing an emerging company in its growth phase.

Profitability Metrics

Net profit margin, gross margin, and operating margin analysis for Crispr Therapeutics Ag...

Market Valuation

P/E ratio, price-to-book, and valuation multiples for Crispr Therapeutics Ag...

Return Metrics

Return on equity (ROE), return on assets (ROA), and capital efficiency for Crispr Therapeutics Ag...

Unlock Financial Analysis

Get complete financial metrics for Crispr Therapeutics Ag

Sign Up Free
AI ANALYSIS AVAILABLE

Unlock Crispr Therapeutics Ag's AI Price Forecast

Join 10,000+ investors using our 67%+ accurate AI predictions

4,000+ Stocks Analyzed
67%+ Accuracy Rate
Daily Updates
Start 30-Day Free Trial →

✓ 30-day free trial • ✓ Cancel anytime

Strategic Market Position

Crispr Therapeutics Ag strategically competes in the highly dynamic Biological Products, (No Diagnostic Substances) marketplace. As a mid-cap company, it occupies an attractive position balancing growth potential with established operations. Mid-caps often represent the 'sweet spot' for investors seeking companies that have proven their business models but still have meaningful runway for expansion. These companies are large enough to have competitive advantages but nimble enough to adapt quickly to market changes.

Industry Competitive Landscape

Crispr Therapeutics Ag competes within the Life Sciences sector, navigating the competitive dynamics and market forces specific to this industry. The company's competitive position depends on its ability to differentiate through product quality, cost efficiency, customer relationships, or other strategic advantages relevant to its specific market segment.

Operational Efficiency

The company currently shows negative free cash flow of $-401 million . Negative free cash flow may reflect heavy investment in growth, working capital needs, or operational challenges. This is common for high-growth companies investing aggressively but warrants attention for mature businesses.

Financial Strength & Leverage

Current ratio of 17.96 demonstrates strong short-term liquidity with current assets significantly exceeding current liabilities. This provides a substantial buffer for meeting near-term obligations and handling unexpected financial needs.

Crispr Therapeutics Ag (CRSP) Fundamental Analysis & Insider Trading Data (Quarterly Financial Reports)

Comprehensive quarterly financial data, earnings trends, insider transactions, and institutional holdings for Crispr Therapeutics Ag stock analysis.

Deep dive into Crispr Therapeutics Ag's financial health, valuation metrics, and operational efficiency to make informed investment decisions.

Understanding Valuation Metrics

What these metrics mean: Valuation metrics help determine if Crispr Therapeutics Ag stock is fairly priced compared to its earnings, assets, and market position.

How to read them: Lower P/E ratios may indicate undervalued stocks, while higher ratios suggest growth expectations. P/B ratio compares market value to book value.

For Crispr Therapeutics Ag:

P/B Ratio 2.52x
Market Cap $4.58B
Book Value/Share $18.82
Revenue/Share $0.04
FCF/Share $-4.16
Understanding Profitability Metrics

What these metrics mean: These ratios measure how efficiently Crispr Therapeutics Ag converts revenue into profit and generates returns for shareholders.

How to read them: Higher ROE/ROA indicate better management efficiency. Margin percentages show profit at different operational levels.

For Crispr Therapeutics Ag: An ROE of -8.9% indicates room for improvement in shareholder value creation.

ROE -8.9%
ROA -5.9%
ROIC -6.6%
Operating Margin -1518.4%
Net Margin -1428.2%
EBT Margin -1426.1%
Tax Rate -0.2%
Understanding Financial Health Metrics

What these metrics mean: These ratios assess Crispr Therapeutics Ag's ability to meet short-term obligations and manage debt levels effectively.

How to read them: Current ratio >2 is generally good, Quick ratio >1 shows strong liquidity. Lower D/E ratios indicate conservative debt management.

For Crispr Therapeutics Ag: A current ratio of 17.96 indicates strong liquidity.

Current Ratio 17.96x
D/E Ratio 0.50x
Financial Leverage 1.50x
Interest Coverage -235.5x
Working Capital $2.31B
Understanding Cash Flow Metrics

What these metrics mean: Cash flow metrics reveal Crispr Therapeutics Ag's ability to generate cash from operations and fund growth initiatives.

How to read them: Positive operating cash flow is crucial. Free cash flow shows money available for dividends, buybacks, or investments.

For Crispr Therapeutics Ag: Free cash flow of $-401M indicates cash challenges that need attention.

Operating Cash Flow -$144M
Free Cash Flow -$401M
Capital Spending -$258M
FCF/Sales -9777.6%
CapEx/Sales 6278.3%
Understanding Operational Efficiency Metrics

What these metrics mean: These ratios measure how effectively Crispr Therapeutics Ag uses its assets and manages working capital.

How to read them: Higher turnover ratios indicate efficient asset utilization. Shorter collection periods show effective credit management.

For Crispr Therapeutics Ag:

Fixed Assets Turnover 0.0x
Understanding Financial Statement Data

What these metrics mean: Key figures from Crispr Therapeutics Ag's income statement and balance sheet showing absolute financial performance.

How to read them: Revenue shows business scale, while margins indicate profitability. Balance sheet items reveal financial structure.

For Crispr Therapeutics Ag: With annual revenue of $4M, Crispr Therapeutics Ag represents a smaller but potentially high-growth operation.

Income Statement
Total Revenue $4M
Operating Income -$171M
Net Income -$161M
R&D Expense $107M
Balance Sheet Highlights (% Of Assets)
Total Current Assets 2448%
Cash & Short-term Investments 423%
Total Liabilities 911%
Short-term Debt 123%
Dividend & Shareholder Information
Shares Outstanding 96M
Growth Metrics (YoY)
Net Income Growth -1428.2%

Latest Crispr Therapeutics Ag Stock News & Market Analysis

Breaking news, analyst reports, and market updates affecting Crispr Therapeutics Ag (CRSP) stock price and investment outlook.

📰 Loading...

Crispr Therapeutics Ag Competitors & Peer Analysis - Life Sciences Sector

Comparative analysis of Crispr Therapeutics Ag against industry peers and competitors in the Life Sciences sector, featuring AI-powered forecasts and key financial metrics.

Company Ticker Symbol 90-Day AI Forecast Market Cap (USD M) P/E Ratio P/B Ratio
ABOS ██% $157M x 1.8x
ABPO ██% $1M x x
ACOG ██% $179M x 3.1x
ADAPY ██% $8M x x
ADMA ██% $1.94B 11.8x 5.0x
ADPT ██% $3.56B x 16.5x
AGEN ██% $238M 3.7x x
AGTX ██% $800K x x
AIM ██% $7M x 3.3x
ALEC ██% $165M x 15.9x
ALGS ██% $29M x 0.9x
ALLO ██% $628M x 2.3x
ALVO ██% $992M x x
AMGN ██% $200.50B 25.7x 21.8x
APGE ██% $10.05B x x
APTOF ██% $4M x x
ARGX ██% $57.22B x x
ARMP ██% $192M x x
ARTV ██% $492M x 5.6x
ATRA ██% $70M x x
ATYR ██% $49M x 0.8x
AURA ██% $745M x 6.9x
AUTL ██% $405M x 3.7x
AVXL ██% $230M x 1.8x
BCAB ██% $6M x x
BCDA ██% $14M x x
BCLI ██% $11M x x
BCRX ██% $2.38B x x
BDTX ██% $105M x 1.0x
BEAM ██% $2.66B x 2.3x
BIIB ██% $29.53B 21.5x 1.6x
BNTX ██% $23.28B x x
CABA ██% $444M x 4.3x
CADL ██% $722M x 5.2x
CCCC ██% $380M x 1.6x
CELZ ██% $5M x 0.9x
CERO ██% $500K x x
CGEM ██% $1.06B x 2.9x
CGEN ██% $221M 3.1x 2.2x
CGON ██% $6.26B x 5.7x
CGTX ██% $86M x 2.9x
CHRS ██% $221M 1.2x 2.8x
CLDI ██% $2M x 0.4x
CLLS ██% $279M x x
CMPX ██% $382M x 2.1x
CPMV ██% $5M x x
CRDF ██% $65M x 1.9x
CRDL ██% $123M x x
CRIS ██% $9M x 0.7x
CRSP ██% $4.58B x 2.5x
CSBR ██% $83M x 19.5x
CVM ██% $21M x 3.0x
DBVT ██% $820M x 5.1x
DNA ██% $489M x 1.1x
DNLI ██% $3.72B x 4.0x
DTIL ██% $189M x 2.5x
DYAI ██% $44M x x
EDIT ██% $419M x 95.0x
ELUT ██% $40M 0.8x 1.8x
ENGN ██% $127M x 0.5x
ENTX ██% $99M x 9.3x
ENZN ██% $59M x 0.3x
ESLA ██% $32M x x
EVAX ██% $25M x x
EXEL ██% $14.12B 16.9x 7.3x
EXOZ ██% $40M x 26.1x
FATE ██% $293M x 1.6x
FDMT ██% $543M x 1.2x
FENC ██% $351M x 9.3x
GILD ██% $162.53B 17.6x 6.9x
GLUE ██% $1.94B x 3.7x
GNTA ██% $80M x 6.4x
GPLB ██% $260K x x
GRML ██% $30M x 0.6x
HALO ██% $9.58B 27.5x 43.6x
HUMA ██% $172M x 14.8x
IBRX ██% $7.75B x x
IKT ██% $366M x 2.2x
IMA ██% $63M x 0.5x
IMCR ██% $1.81B x 4.6x
IMTX ██% $1.25B x x
IMVT ██% $8.03B x 9.4x
INAB ██% $12M x 0.5x
INKT ██% $50M x x
INMB ██% $46M x 2.3x
INTS ██% $11M x 1.1x
IOVA ██% $2.25B x 3.1x
IPSC ██% $391M x 1.5x
IVVD ██% $172M x 0.9x
JATT ██% $88M x 0.4x
JSPR ██% $24M x 7.1x
KLRS ██% $90M x 1.3x
KOD ██% $2.55B x 22.7x
KRYS ██% $9.64B 42.8x 7.6x
KYMR ██% $9.07B x 5.9x
KYTX ██% $441M x 2.3x
LCTX ██% $267M x 5.0x
LENZ ██% $158M x 0.6x
LIFE ██% $1.87B x 32.2x
LIMN ██% $7M x x
LONA ██% $68M x 1.4x
LXEO ██% $349M x 1.5x
MAZE ██% $1.53B x 4.5x
MESO ██% $2.09B x x
MGTX ██% $986M x x
MGX ██% $46M x 0.3x
MOLN ██% $160M x x
MRNA ██% $22.64B x 3.1x
NBIX ██% $17.52B 26.2x 5.1x
NMRA ██% $281M x 4.0x
NVAX ██% $1.29B x x
OCGN ██% $430M x 74.0x
OTLK ██% $247M x x
PALI ██% $338M x 2.7x
PASG ██% $16M x 1.3x
PCVX ██% $8.03B x 2.7x
PHGE ██% $2M x x
PLUR ██% $19M x x
PLX ██% $189M 12.3x 2.8x
PMCB ██% $6M x 0.2x
PRME ██% $536M x 7.0x
PROK ██% $459M x x
PTHS ██% $96M x 2.7x
QGEN ██% $8.99B x 2.4x
QNCX ██% $18M 2.1x 1.1x
REPL ██% $865M x 5.2x
RGEN ██% $7.76B 151.0x 3.7x
RGNX ██% $656M x 31.1x
RLAY ██% $4.14B x 6.5x
RVMD ██% $37.78B x 25.2x
RXRX ██% $1.60B x 1.6x
SABS ██% $274M x 1.2x
SANA ██% $866M x 7.3x
SCLX ██% $52M x x
SCNI ██% $1M x 0.2x
SGMO ██% $29M x x
SGMOQ ██% $25M x x
SLDB ██% $804M x 2.2x
SLXN ██% $3M x 8.7x
SNTI ██% $13M x 5.2x
SRRK ██% $5.89B x 21.4x
SRZN ██% $231M x x
STRO ██% $391M x x
TARA ██% $226M x 1.3x
TARS ██% $2.52B x 7.2x
TCRX ██% $52M x 0.5x
TECH ██% $11.23B 102.5x 5.4x
TECX ██% $594M x 2.6x
TIL ██% $48M x 0.4x
TNYA ██% $168M x 1.6x
TSHA ██% $1.67B x 7.9x
TVGN ██% $20M x x
TWST ██% $5.75B x 12.6x
VACH ██% $541M 80.4x x
VALN ██% $516M x x
VCEL ██% $2.30B 107.1x 6.5x
VIR ██% $1.51B x 1.9x
VIVS ██% $2M x 0.4x
VOR ██% $1.03B x x
VXRT ██% $121M 3.3x 1.3x
VYGR ██% $186M x 1.1x
WINT ██% $340K x x
XFOR ██% $376M x 2.2x
ZEOX ██% $14M x 19.4x
ZIVO ██% $19M x x
ZURA ██% $502M x 2.3x
Reveal all forecasts See exact % predictions for all competitors
Sign up free

Frequently Asked Questions - Crispr Therapeutics Ag Stock Forecast

How accurate are Crispr Therapeutics Ag stock predictions?

Our AI model shows a -9% Spearman correlation coefficient for CRSP predictions, based on advanced machine learning algorithms trained on over 10 years of market data. This measures the strength of the monotonic relationship between predicted and actual price movements.

What factors influence Crispr Therapeutics Ag stock price forecasts?

Our analysis considers Crispr Therapeutics Ag's financial metrics, Life Sciences sector trends, market sentiment, technical indicators, earnings data, and macroeconomic factors affecting stock performance.

Is Crispr Therapeutics Ag a good investment in 2025?

Based on our AI analysis, Crispr Therapeutics Ag shows potential for various market scenarios. Consider your risk tolerance, investment timeline, and portfolio diversification before making investment decisions.

How often are Crispr Therapeutics Ag forecasts updated?

Crispr Therapeutics Ag stock forecasts are updated daily using real-time market data, ensuring you receive the most current AI-powered predictions and investment insights.

Want a simpler view of Crispr Therapeutics Ag?

View simplified analysis on AI Stock Finder →

My Portfolio

Investment Dashboard

Loading your portfolio...